Stock Scorecard



Stock Summary for United Therapeutics Corp (UTHR) - $364.33 as of 11/20/2024 8:50:21 PM EST

Total Score

18 out of 30

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for UTHR

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for UTHR

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for UTHR

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for UTHR

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for UTHR (69 out of 90)

Stock Price Rating (Max of 10) 10
Historical Stock Price Rating (Max of 10) 10
Stock Price Trend (Max of 10) 10
Book Value (Max of 10) 10
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 8
Trading Volume (Max of 10) 4
Price to Earnings (Max of 10) 8

Latest News for for UTHR

Should You Invest in the Invesco Biotechnology & Genome ETF ( PBE ) ? 11/20/2024 11:20:00 AM
Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update 11/13/2024 11:30:00 AM
Is Invesco Biotechnology & Genome ETF ( PBE ) a Strong ETF Right Now? 11/11/2024 11:20:00 AM
MannKind ( MNKD ) Q3 2024 Earnings Call Transcript 11/8/2024 4:15:00 AM
MannKind Corporation Reports 2024 Third Quarter Financial Results and Provides Business Update - MannKind ( NASDAQ:MNKD ) 11/7/2024 9:02:00 PM
United Therapeutics ( UTHR ) is a Top-Ranked Growth Stock: Should You Buy? 11/5/2024 2:45:00 PM
United Therapeutics ( UTHR ) is a Top-Ranked Value Stock: Should You Buy? 11/4/2024 2:40:00 PM
United Therapeutics Q3 Earnings & Sales Beat Estimates 11/1/2024 2:19:00 PM
United Therapeutics ( UTHR ) Q3 Earnings and Revenues Top Estimates 10/30/2024 11:40:00 AM
Is SPDR S&P Biotech ETF ( XBI ) a Strong ETF Right Now? 10/30/2024 10:20:00 AM

Financial Details for UTHR

Company Overview

Ticker UTHR
Company Name United Therapeutics Corp
Country USA
Description United Therapeutics Corporation, a biotechnology company, is dedicated to the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company is headquartered in Silver Spring, Maryland.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 9/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 364.33
Price 4 Years Ago 151.79
Last Day Price Updated 11/20/2024 8:50:21 PM EST
Last Day Volume 192,465
Average Daily Volume 353,593
52-Week High 417.81
52-Week Low 208.62
Last Price to 52 Week Low 74.64%

Valuation Measures

Trailing PE 15.77
Industry PE 22.60
Sector PE 40.32
5-Year Average PE 16.74
Free Cash Flow Ratio 4.85
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 4.58
Total Cash Per Share 75.05
Book Value Per Share Most Recent Quarter 136.74
Price to Book Ratio 2.66
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 5.82
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 7
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 44,644,500
Market Capitalization 16,265,330,685
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 6.35%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 18.80%
Annual Earnings Growth 35.40%
Reported EPS 12 Trailing Months 22.78
Reported EPS Past Year 18.41
Reported EPS Prior Year 19.84
Net Income Twelve Trailing Months 1,110,900,000
Net Income Past Year 984,800,000
Net Income Prior Year 727,300,000
Quarterly Revenue Growth YOY 22.90%
5-Year Revenue Growth 6.86%
Operating Margin Twelve Trailing Months 0.55

Balance Sheet

Total Cash Most Recent Quarter 3,350,500,000
Total Cash Past Year 3,009,000,000
Total Cash Prior Year 2,869,400,000
Net Cash Position Most Recent Quarter 2,950,500,000
Net Cash Position Past Year 2,309,000,000
Long Term Debt Past Year 700,000,000
Long Term Debt Prior Year 800,000,000
Total Debt Most Recent Quarter 400,000,000
Equity to Debt Ratio Past Year 0.90
Equity to Debt Ratio Most Recent Quarter 0.94
Total Stockholder Equity Past Year 5,984,800,000
Total Stockholder Equity Prior Year 4,796,700,000
Total Stockholder Equity Most Recent Quarter 6,100,900,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months 898,100,000
Free Cash Flow Per Share Twelve Trailing Months 20.12
Free Cash Flow Past Year 747,600,000
Free Cash Flow Prior Year 663,700,000

Options

Put/Call Ratio 0.33
Has Options Options Chain
Liquidity Rating None

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 12.60
MACD Signal 9.51
20-Day Bollinger Lower Band 303.28
20-Day Bollinger Middle Band 349.58
20-Day Bollinger Upper Band 395.88
Beta 0.56
RSI 67.32
50-Day SMA 283.97
150-Day SMA 244.45
200-Day SMA 230.59

System

Modified 11/19/2024 3:17:45 PM EST